CD274 and head and neck squamous cell carcinoma: HB-200 has been studied in combination with pembrolizumab as a first-line treatment for HPV-16- and PD-L1-positive recurrent/metastatic HNSCC (n = 42), most cases of which were checkpoint inhibitor-naïve (95%).